Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308759 · ClinicalTrials.gov registry record · Phase 3
An Innovative Conversational Agent (Quitbot) for Smoking Cessation
A Phase 3 study of Cigarette Smoking-Related Carcinoma, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 1,647
- Enrollment target
- 1
- Study location
NCT04308759: Active Phase 3 study of Cigarette Smoking-Related Carcinoma, sponsored by Fred Hutchinson Cancer Center.
NCT04308759 is a Phase 3 study of Cigarette Smoking-Related Carcinoma that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 1,647 participants, above the 389-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (323% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04308759, a Phase 3 study of Cigarette Smoking-Related Carcinoma, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,647 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.
Primary Outcome
The primary endpoint is 30-day point prevalence abstinence for cigarette smoking at 12 months post-randomization. At 12 months, smoking abstinence is assessed by asking participants: "When was the last time you smoked, or even tried, a cigarette?" Response choices are "Earlier today", "24 hours ago", "2-7 days ago", "8-30 days ago", and "Over 30 days ago". Participants reporting no cigarette consumption in the past 30 days are considered abstinent for the 30-day outcome. Missing outcome data are
Conditions Studied
Interventions
- OTHER Experimental Smoking Cessation Program
- OTHER Control Smoking Cessation Program
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,647 participants |
| Start Date | 2022-07-24 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 3 |
What the registry record for NCT04308759 still lists
NCT04308759 is an interventional study that assigns participants to a tested intervention. Its 1,647 participants enrollment target places it among the larger protocols in the corpus, above the 389-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (323% higher).
The record links to 1 condition, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Experimental Smoking Cessation Program is the first listed.
NCT04308759 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04308759 about?
NCT04308759 is a clinical study titled "An Innovative Conversational Agent (Quitbot) for Smoking Cessation". This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.
What is the current status of trial NCT04308759?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,647 participants. The study started on 2022-07-24. Estimated completion is 2026-05-01.
What conditions does trial NCT04308759 study?
This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma.
What interventions are being tested in trial NCT04308759?
The interventions under investigation include: Experimental Smoking Cessation Program (OTHER), Control Smoking Cessation Program (OTHER).
Who is sponsoring clinical trial NCT04308759?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04308759 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04308759's enrollment target sits among peer trials
1,647 2nd of 21 the highest of 21 other Cigarette Smoking-Related Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cigarette Smoking-Related Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
RECRUITING · Phase 3
-
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
RECRUITING · NA
-
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
RECRUITING
-
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
RECRUITING · Early Phase 1
-
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
RECRUITING · Phase 4
-
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI